SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as a crypto embodying cannabis culture, community, and freedom. Community members emphasize its focus on positivity, long-term vision, and real-world applications within the cannabis space. The conversation highlights Weedcoin as more than just a token, but as a movement for culture and community.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending due to recent Phase 3 trial data for their skin drug, Sonelokimab, which showed mixed results. While one trial succeeded, another was impacted by a high placebo response, leading to community discussion around potential regulatory implications and future prospects. Community members are actively debating the approvability of the drug, potential buyout scenarios, and comparing it to competitors in the sector.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement, with the community actively discussing whether the stock can sustain its momentum. Some traders believe the financing deal could be dilutive, while others are optimistic about a potential short squeeze given the tight float. Overall, traders are closely monitoring JFB for potential continuation or pullback.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders weigh the potential impacts of a looming government shutdown and speculate on its effects on the market, particularly regarding the release of upcoming jobs data. Community discussions revolve around potential market reactions, with some anticipating a bullish outcome if a shutdown is averted, while others are bracing for volatility and a possible downturn, especially given concerns about high stock valuations and AI-driven market dynamics.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following positive Phase 3 trial results for its oral Wegovy pill, showing similar weight loss efficacy to the injectable version; the community is discussing the potential for increased demand and market dominance if approved. However, some analysts point to downgrades citing slower growth, competition, and margin pressure, creating a debate around the company's future prospects. Investors are weighing the potential impact of these factors against Novo Nordisk's strong position in the growing GLP-1 market.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to a massive volume spike and significant price volatility, with community members weighing entry points. Discussions revolve around the potential impact of a competitor's ($MLTX) data and speculation about future catalysts. Bullish sentiment is fueled by analyst ratings and price target increases.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus is trending following news of Genmab's acquisition of the company for $8 billion, or $97 per share, sparking excitement among biotech investors. The community is buzzing about the buyout price and potential implications for other companies in the sector. Some investors are expressing regret for selling their shares earlier, while others are drawing comparisons to similar acquisitions.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

MSOX is trending as investors discuss potential catalysts for cannabis stocks, including possible rescheduling and Trump's stance on the industry. Community members are weighing the risks and potential rewards, with some anticipating significant gains while others remain cautious due to the sector's volatility. Bullish sentiment seems to be building amid speculation of upcoming news and a possible short squeeze.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending as traders anticipate updates from the company's nomlabofusp clinical development program for Friedreich's ataxia, expected to be released with a conference call. Community discussions revolve around the potential for positive clinical outcomes and speculation regarding leaked data, with some noting unusual options activity and potential for a significant price swing. Bullish sentiment seems to be building.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending due to the upcoming presentation of topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults. The community anticipates positive results, with some predicting a significant price increase if the data is favorable. Bullish sentiment is further fueled by unusual options activity and mentions of a potential catalyst driving momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Portfolio Rationalization Work Wonders for COMM Stock?

CommScope divests key units, boosts ANS and RUCKUS, and expands through acquisitions to strengthen growth and innovation.

Ciena's Stock Skyrockets 143% in 12 Months: Is More Upside Left?

CIEN shares surge 143% in a year, fueled by AI-driven demand, cloud adoption and record interconnect growth.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

CIEN Q3 Earnings & Sales Top, Stock Up on 91% Y/Y Bottom-Line Growth

Ciena posts a revenue and earnings surge, lifts outlook with AI-driven demand and sees shares jump over 23% on strong fiscal Q3 2025 results.

Here's Why Viav Solutions (VIAV) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Viavi Surpasses Q4 Earnings Estimates on Solid Revenue Growth

Viavi beats Q4 estimates as revenue climbs 15%, led by strong gains in NSE and OSP segments despite macro headwinds.

Zacks Industry Outlook Highlights Corning, Viavi Solutions and Ooma

Corning, Viavi, and Ooma stand out in the communications sector despite industry headwinds from costs, tariffs, and demand volatility.

Viav Solutions (VIAV) Beats Q4 Earnings and Revenue Estimates

Viav Solutions (VIAV) delivered earnings and revenue surprises of +8.33% and +1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Communication Stocks Likely to Beat Industry Conundrums

Increased fiber densification, cloud focus and accelerated pace of 5G deployment should help the Zacks Communication - Components industry thrive despite short-term headwinds. GLW, VIAV and OOMA are well-positioned to make the most of the demand for seamless connectivity solutions.

AudioCodes (AUDC) Q2 Earnings Lag Estimates

AudioCodes (AUDC) delivered earnings and revenue surprises of -17.65% and +2.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viavi Solutions, Inc. engages in the provision of network test, monitoring, and assurance solutions for communications service providers, enterprises, network equipment manufacturers, government and avionics. It operates through the following segments: Network and Service Enablement, and Optical Security and Performance. The Network and Service Enablement segment provides an integrated portfolio of testing, monitoring, assurance and security solutions to help build, maintain and optimize telecom and datacom networks. The Optical Security and Performance segment leverages its core optical coating technologies and volume manufacturing capability to design, manufacture and sell technologies for the anti-counterfeiting, 3D sensing, government and aerospace, automotive and industrial markets. The company was founded in 1979 and is headquartered in Chandler, AZ.

Viavi Solutions Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.13	--	--	N/A
Q4 '25	$0.12	$0.13	12.27%	BEAT
Q3 '25	$0.12	$0.15	26.51%	BEAT
Q2 '25	--	$0.13	--	N/A
Q1 '25	$0.06	$0.06	0.91%	BEAT

VIAV
Viavi Solutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest VIAV News

VIAV Viavi Solutions Inc